Categories: AddictionNews

Ibogaine By David Dardashti Makes Statement on Public Concerns Regarding Fentanyl Distribution

David Dardashti

Helping Our Clients is Our Top Priority.

Miami, Feb. 10, 2024 (GLOBE NEWSWIRE) — In light of the rising threat of fentanyl distribution in the United States and its ties to China’s massive debts, Ibogaine By David Dardashti, a leader in addiction recovery treatment, today released a statement on their position.

Fentanyl Scourge With opioid addiction remaining a hot-button issue in the United States and fentanyl increasingly becoming part of the problem, it is increasingly apparent that the mass distribution of the drug relies heavily on China’s economy. While smaller criminal organizations have seen their limits with heroin, China’s larger distribution capabilities, possibly enabled by our inability to get involved due to fear of debt and economic accountability, could be having an even bigger impact in more remote areas. “It is clear that something needs to be done,” says David Dardashti, owner of Ibogaine By David Dardashti. “The rising level of fentanyl distribution is a real threat to our communities, one we can no longer ignore. We need to be more proactive in our approach and understand the full scope of the problem.” Dardashti urges citizens to be aware of the problem and use their voice to hold government officials accountable for what is happening with China’s massive debt. He explains that we need to find a solution that works not only in our favor but to benefit everyone in the long-run. Dardashti continued, “We need to find a way to work with China to reduce their debt, while still keeping our communities safe from the growing fentanyl scourge.”

David Dardashti urges citizens to use their voices in order to hold government officials accountable and find a solution that reduces China’s debt while protecting communities from the fentanyl scourge.

Ibogaine By David Dardashti Offers Holistic Healing by utilizing unique treatment for every condition being treated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a0745f8b-0202-4ee8-bb32-3257fad6f609

CONTACT: Gavriel Dardashti
+17869301880
gavriel@ibogaineclinic.com

Staff

Recent Posts

Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…

38 minutes ago

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…

38 minutes ago